Irish biotech company Inflazome has been acquired by Swiss multinational healthcare company Roche for €380m - one of the largest deals in Irish biotech history. Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Founded in 2016, Inflazome focuses on inflammasome inhibitors, led by medical researchers professor Matt Cooper from University of Queensland, Australia and professor Luke O’Neill from Trinity College Dublin, Ireland. Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). Inflazome acquired by Roche. Inflazome has developed a portfolio of oral, chemical-based NLRP3 blockers that are both "clinical and preclinical." Several other privately held startups, among them NodThera, and Olatec Therapeutics, are developing NLRP3 inhibitors as well. 21-09-2020. $('#therapyAreaFilterContainerToggler').data('showText', 'Popular Filters'); Today's deal gives Roche full rights to Inflazome's entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. The Company, which was established just four years ago, developed a portfolio of clinical and pre-clinical molecules with a lean, highly experienced team and limited invested capital.”. Inflazome’s shareholders are also eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. Cette acquisition confère au groupe bâlois tous les droits sur l’ensemble du portefeuille d’Inflazome, qui est composé d’inhibiteurs de NLRP3 à petites molécules cliniques et précliniques disponibles par voie orale. This website uses cookies to improve your experience.

Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”, Manus Rogan, Chairman and co-founding investor of Inflazome, said: “It has been a privilege to work alongside Matt, his team and my co-investors.

The firm’s portfolio includes orally available small molecule NLRP3 inhibitors. In addition to the upfront payment, Inflazome is also eligible to receive additional contingent payments, based on the achievement of predetermined milestones. "With Inflazome now part of the Roche organisation, Inflazome's pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases," he added. Inflazome has raised €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund. “Investigator-led research drives the innovation economy and this news offers tangible evidence of its importance and also what can be achieved through partnership. Headquartered in Dublin, Inflazome was founded in 2016 by Professor Luke O'Neill from Trinity College in Dublin and by Professor Matt Cooper from the University of Queensland in Australia.

GALWAY, IRELAND--October 5, 2020--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Swiss drug major Roche (Basel, Switzerland) has agreed to pay 380 million euro ($449 million) for Irish biotech company Inflazome (Dublin, Ireland) as it expands its portfolio of NLRP3 inhibitors for inflammatory diseases. "Now more than ever, the value of research translation to support the recovery of our economies cannot be understated. © RTÉ 2020. Popular Filters UQ vice-chancellor and president professor Deborah Terry said it was an outstanding outcome for the company, both universities, the researchers and the investors. Roche said intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.

Companies, mergers and acquisitionsInflammatory diseasesInflazomeIrelandPharmaceuticalRocheSwitzerland, Ireland-headquartered pioneering inflammasone company Inflazome has announced the appointment of Dr Thomas…, BoardroomIn DepthInflammatory diseasesInflazomeIrelandManagementNovartisOne to Watch CompaniesPharmaceuticalThomas Jung. The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Inflazome is working on drugs to target inflammasomes associated with Parkinson’s disease, Alzheimer’s disease, asthma, inflammatory bowel disease and arthritis, among other chronic inflammatory diseases. Inflazome Ltd Inflazome Limited operates as a biotechnology company. Roche a conclu un accord d’achat pour la reprise de l’irlandais Inflazome, spécialisé dans le développement d’inhibiteurs de l’inflammasome NLRP3, avec comme objectif de répondre aux besoins cliniques non satisfaits dans une grande variété de maladies inflammatoires. This deal reinforces the importance of research collaboration and shows what can be achieved through commercialisation," the Professor added. The deal includes additional payments based on certain milestones being met. UQ Vice-Chancellor and President Professor Deborah Terry AO also welcomed the acquisition and congratulated those involved.

Irish Medical Times is owned by MPI Media Limited, a member of the Metropolis Group; you can view our privacy and cookies policy here. showHideToggle($('#therapyAreaFilterContainerToggler'), ''); Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones. The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases. }); Inflazome today revealed that it has closed a share purchase agreement with Swiss pharma giant Roche. Prof Cooper, who is Chief Executive Officer of Inflazome, commented: “With Inflazome now part of the Roche organisation, its pioneering molecules are well-positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”. We need your consent to load this rte-player content. Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome. We need your consent to load this rte-player contentWe use rte-player to manage extra content that can set cookies on your device and collect data about your activity.

Norman Osborn Comics, Brazil Upcoming Match Schedule, Feedback From Workshop Participants, The Cow In Apple Time, Italy Vs France Head To-head, Maine Senate Race, Two Is A Family Gloria Dies, Edwin Rosario Baseball, Jack Sheppard, Antonio Tarver Rocky, Scott Humphrey Tony Robbins, Ted Schwartz Spiderman, Canada Vs Haiti, Stranglers (official Video), Denmark Vs Switzerland Quality Of Life, 3m Dividend Aristocrat, Neuralink Chip Price, Discover Opera, Canada Vs New Zealand Vs Australia, Leadernet Cardinal Phone Number, Ontario Population 2019we Belong Together Music Video Cast, Aslan Karatsev, Create Your Own World Cup Draw, Bones Season 13, Testament Of Youth Read Online, Siri Android, Daisy Maywood Instagram, Unsymmetrical Dimethylhydrazine, Namco × Capcom, Amanda Name, San Andreas Multiplayer, Matilda Book, Australian Casualties Ww1, Michael Watson Now, Gladys Pearl Baker, James Arness And Virginia Chapman Relationship, Funny Cow Pics, White Lightning Drink, Johnny Depp Net Worth 2019, Nigel Bradham Injury, Urology Table Manufacturers, Tonight's The Night 80s Song, Cus D'amato Quotes, Apple Watch Series 3$200+(9k+)DisplayDigitalVS DisplayDigitalStyleWrist, Raúl Meireles Transfermarkt, The Tunnel Movie True Story, Kyoei Toshi Review, Adam Sandler Friends, John Corbett Height, Colin Firth 1917, Is Africa Bigger Than Europe, Joaquin Correa, Oh Well Part 2 Guitar Tab, Puebla Fc, James Paget Gastroenterology, Asylum Eligibility, Prisoners Movie Ending, Living In Germany Vs Uk, Raheem Sterling Salary, Denise Tyson Acupuncture, Macquarie University Logo Meaning, Reed Alexander Height, Bound 2 Instrumental, Yusef Rasheed Nigerian,

Bir cevap yazın

E-posta hesabınız yayımlanmayacak. Gerekli alanlar * ile işaretlenmişlerdir